Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 3.2% – Should You Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price traded down 3.2% on Tuesday . The stock traded as low as $0.37 and last traded at $0.39. 45,372,542 shares changed hands during mid-day trading, an increase of 52% from the average session volume of 29,892,227 shares. The stock had previously closed at $0.40.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research note on Monday. They set a “hold” rating for the company.

Tonix Pharmaceuticals Trading Down 4.4 %

The stock has a market cap of $72.01 million, a P/E ratio of -0.01 and a beta of 2.23. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The business’s 50 day simple moving average is $0.21 and its two-hundred day simple moving average is $0.41.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The business had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.